FDA Expands Enhertu Approval to HER2-Ultralow Breast Cancer

(MedPage Today) -- The FDA expanded the approval of trastuzumab deruxtecan (T-DXd, Enhertu) to include treatment of unresectable/metastatic hormone receptor (HR)-positive, HER2-low/ultralow breast cancer.
Approval stipulates use in patients with...